Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy | Zendy

Barbara Pistilli | Zendy; Timothy Pluard | Zendy; Ander Urruticoechea | Zendy; Daniele Farci | Zendy; Anthony Kong | Zendy; Thomas Bachelot | Zendy; Stephen Chan | Zendy; Hyo S. Han | Zendy; G. Jerusalem | Zendy; Patrick Urban | Zendy; Douglas Robinson | Zendy; Sylvie Le Mouhaër | Zendy; Emmanuelle di Tomaso | Zendy; Cristian Massacesi | Zendy; Cristina Saura | Zendy

Open Access

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy

Author(s) -

Barbara Pistilli,

Timothy Pluard,

Ander Urruticoechea,

Daniele Farci,

Anthony Kong,

Thomas Bachelot,

Stephen Chan,

Hyo S. Han,

G. Jerusalem,

Patrick Urban,

Douglas Robinson,

Sylvie Le Mouhaër,

Emmanuelle di Tomaso,

Cristian Massacesi,

Cristina Saura

Publication year - 2017

Publication title -

breast cancer research and treatment

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.908

H-Index - 154

eISSN - 1573-7217

pISSN - 0167-6806

DOI - 10.1007/s10549-017-4596-7

Subject(s) - trastuzumab , medicine , oncology , breast cancer , metastatic breast cancer , cancer

A Phase Ib study in patients with trastuzumab-resistant, human epidermal growth factor receptor-2- (HER2)-positive advanced breast cancer defined the recommended Phase II dose of buparlisib as 100 mg/day in combination with 2 mg/kg weekly trastuzumab, and reported preliminary signs of clinical activity. Here we present results from the Phase II portion.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research